Vitamin K-2 100 mcg by GNC — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Softgel(s) Serving Size

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K-2

100 mcg

✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.1mg

Other Ingredients

Soybean Oil Gelatin Glycerin Caramel color Titanium Dioxide

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Women (not pregnant or lactating) Gluten Free Dairy Free Sugar Free

Product Information

📋 Directions for Use

Directions: As a dietary supplement, take one softgel capsule daily.

⚠️ Warnings & Precautions

Keep out of reach of children.

Contains: Soybeans.

Warning: Do not use if pregnant, nursing or are allergic or contraindicated to aspirin. If you are taking aspirin or blood thinning or other medication, consult your healthcare professional before using this product.

Warning: Do not use if pregnant, nursing or are allergic or contraindicated to aspirin.

Discontinue use two weeks prior to surgery, or if upset stomach occurs.

🧪 Formulation Notes

No sugar, no starch, no artificial flavors, no preservatives, sodium free, no wheat, gluten free, no corn, no dairy. GF Gluten Free

Supports the bone-building process

Features superior menaquinone-7

Additional Information

Store in a cool, dry place.

60-day supply

Product Details

UPC / SKU 0 48107 17701 0

DSLD Entry Date 2020-06-24

Product Type Vitamin

Form Softgel Capsule

Brand GNC

DSLD ID 225813

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation